-
Valeant's 2011 Outlook Impresses - Analyst Blog
Friday, January 7, 2011 - 12:06pm | 467Valeant Pharmaceuticals International (VRX) recently provided guidance for fiscal 2011. The company also provided guidance for fourth quarter 2010 and fiscal 2010. 2011 Outlook Valeant expects to earn $2.25 to $2.50 per share on total revenue of $2.1 billion – $2.3 billion in 2011. The Zacks...
-
Valeant's 2011 Outlook Impresses - Analyst Blog
Friday, January 7, 2011 - 11:45am | 467Valeant Pharmaceuticals International (VRX) recently provided guidance for fiscal 2011. The company also provided guidance for fourth quarter 2010 and fiscal 2010. 2011 Outlook Valeant expects to earn $2.25 to $2.50 per share on total revenue of $2.1 billion – $2.3 billion in 2011. The Zacks...
-
Morgan Stanley Raises ILMN Target To $78
Thursday, January 6, 2011 - 11:48am | 145Morgan Stanley is raising its target on Illumina, Inc. (NASDAQ: ILMN) to $78 and continue to like the stock for 2011. “There are three keys to our positive thesis,” Morgan Stanley writes. “1) an emerging and underappreciated margin leverage story with Illumina on track to roughly double earnings...
-
BioDelivery Sciences HiresSenior VP of Manufacturing Operations
Thursday, January 6, 2011 - 11:43am | 61BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the hiring of Steven Dykstra as Senior Vice President of Manufacturing Operations. In this capacity, Mr. Dykstra will lead BDSI's oversight of all manufacturing operations for the company. Mr. Dykstra will report directly to Dr...
-
Options Brief: AMAG Pharmaceuticals (AMAG)
Thursday, January 6, 2011 - 11:34am | 90Shares of AMAG Pharmaceuticals (NASDAQ: AMAG) are higher on the session by 1.44%, trading at $18.29. Overall call volume is now running at 6.67x the daily average, with 63% of all calls traded being purchases on the offer. 1,747 contracts have traded on the session so far. AMAG Pharmaceuticals,...
-
SeraCare Life Sciences Secures $20 Million Credit Facilities
Thursday, January 6, 2011 - 10:31am | 70SeraCare Life Sciences, Inc. (Nasdaq: SRLS) today announced that it has entered into a loan agreement that provides senior secured credit facilities in the aggregate amount of $20.0 million with Middlesex Savings Bank and Commerce Bank and Trust Company. Subject to the terms of the loan agreement...
-
eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance
Wednesday, January 5, 2011 - 11:02am | 49ERT (Nasdaq: ERES) announced that its eC-SSRS solution facilitates compliance with the newly introduced Food and Drug Administration guidance document entitled "Suicidality: Prospective Assessment of Occurrence in Clinical Trials." A copy of this guidance can be downloaded from www.ert.com.
-
Index Shows Companies Are Building Again
Wednesday, January 5, 2011 - 2:00am | 292Looking for a reason to be bullish on construction materials and equipment stocks? Take a look at the Architecture Billings Index (ABI) published by the American Institute of Architects. The ABI registered a score of 52 in November, up over 6 percent from the October level of 48.7, the index's...
-
Recall of Liver Drug by CPIX - Analyst Blog
Tuesday, January 4, 2011 - 11:39am | 392Recently, Cumberland Pharmaceuticals Inc. (CPIX) announced that it is recalling 6 lots of liver failure injection, Acetadote, on a voluntary basis. Acetadote is approved for counteracting overdoses of acetaminophen. Cumberland Pharma also stated that the decision to recall 6 lots of the...
-
Recall of Liver Drug by CPIX - Analyst Blog
Tuesday, January 4, 2011 - 11:00am | 392Recently, Cumberland Pharmaceuticals Inc. (CPIX) announced that it is recalling 6 lots of liver failure injection, Acetadote, on a voluntary basis. Acetadote is approved for counteracting overdoses of acetaminophen. Cumberland Pharma also stated that the decision to recall 6 lots of the...
-
AMRI Announces Agreement with Genentech
Tuesday, January 4, 2011 - 9:03am | 43AMRI (NASDAQ: AMRI) announced today a research and licensing agreement with Genentech, a member of the Roche Group, for a family of antibacterial compounds discovered from AMRI's proprietary research of its natural products sample collection.
-
J.P Morgan Downgrades Affymetrix To Underweight
Tuesday, January 4, 2011 - 8:51am | 180Affymetrix (NASDAQ: AFFX)endured a difficult 2010, particularly in 2Q as a result of weakness in Europe, as well as competition in the microarray business. While results in 2H10 showed some signs of stabilization, the broader risk of technology obsolescence from low-cost sequencing and other...
-
J.P. Morgan Raises Target On Illumina, Inc. (ILMN)
Tuesday, January 4, 2011 - 8:25am | 37J.P. Morgan Chase & Co. has an Overweight rating on Illumina, Inc. (NASDAQ: ILMN), but raised the price target to $68 from $57. Shares of ILMN gained $1.00 yesterday to close at $64.34.
-
JP Morgan Downgrades Affymetrix To Underweight
Tuesday, January 4, 2011 - 7:52am | 19JP Morgan has downgraded Affymetrix (NASDAQ: AFFX) from Neutral to Underweight.
-
CNOOC's CBM Endeavor - Analyst Blog
Thursday, December 30, 2010 - 12:33pm | 543China National Offshore Oil Corporation (or CNOOC Group), the parent company of CNOOC Ltd. (CEO), is heading toward an agreement to acquire 50% interest in China United Coal Bed Methane Company Limited (“CUCMB”) for 1.2 billion yuan ($181.2 million). The move reflects the group's endeavor to...